Clinical Advances in Cardiovascular Disease Risk Reduction

Epidemiological and clinical data linking low-density lipoprotein cholesterol (LDL-C) with cardiovascular (CV) disease are well established. Numerous primary and secondary prevention trials have demonstrated that reduction in LDL-C levels leads to a significant decrease in cardiovascular event rates. However, patients may not be able to achieve target LDL-C goals and remain at a substantial risk for CV events. The Clinical Advances in Cardiovascular Disease Risk Reduction curriculum is designed to provide education on the latest clinical advances in effective LDL-C-lowering strategies.

Reducing Risk to Prevent Cardiovascular Events: A Clinical Assessment for the Community Cardiologist CME
Clinical self-assessment in managing complex dyslipidemia in response to new information and changes in the pattern of disease.
October 1, 2013
CV Risk Reduction: Approaches for Cardiologists in the Era of the Affordable Care Act CME
Join Dr Clyde Yancy as he discusses the potential impact and important considerations of the Affordable Care Act for cardiologists.
Aug 21, 2013
Advances in Dyslipidemia Management in the Complex Patient CME
Drs Bays, Cho, and Davidson discuss current advances in the management of dyslipidemia and LDL-C lowering in complex patients.
Aug 20, 2013
Clinical Cases of Mixed Dyslipidemia: Perspectives From a Community Cardiologist CME
Drs Nicholls and Rocco discuss the primary role of LDL-C-lowering therapy in the management of patients with mixed dyslipidemia.
May 14, 2013

Steering Committee Members

Michael H. Davidson, MD
Clinical Professor of Medicine; Director, Preventive Cardiology, Pritzker School of Medicine,
The University of Chicago,
Chicago, Illinois
Robert H. Eckel, MD
Professor of Medicine, University of Colorado Anschutz Medical Campus; Director, Lipid Clinic, University of Colorado Hospital, Aurora, Colorado

Darren K. McGuire, MD, MHSc
Associate Professor, University
of Texas Southwestern Medical
Center at Dallas
Stephen J. Nicholls, MBBS, PhD, FRACP
Professor of Cardiology, SAHMRI Heart Foundation Heart Disease Theme Leader, South Australian Health & Medical Research Institute, Adelaide, Australia

Supported by an independent educational
grant from Merck & Co.

Downloadable Slide Kit

Cardiovascular Disease Risk Reduction Advances in Dyslipidemia
Overview of statin add-on and other therapeutic approaches for CV risk reduction.
Shedding Light on HDL: Myths and Controversies
Overview of HDL and latest clinical trials on CV risk reduction.

Steering Committee

Michael H. Davidson, MD

Michael H. Davidson, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amgen Inc.; AstraZeneca Pharmaceuticals LP; Merck & Co., Inc.; Sanofi
Owns stock, stock options, or bonds from: Omthera Pharmaceuticals, Inc.

Robert H. Eckel, MD

Robert H. Eckel, MD, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Amylin Pharmaceuticals, Inc.; Lilly USA, LLC; Novo Nordisk; Sanofi

Darren K. McGuire, MD, MHSc

Darren K. McGuire, MD, MHSc, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Roche; Daiichi Sankyo, Inc.; Genentech, Inc.; Sanofi, Novo Nordisk; Pfizer Inc; Regeneron Pharmaceuticals, Inc.
Received grants for clinical research from: Roche; Genentech, Inc.; Lilly USA, LLC; Daiichi Sankyo; Novo Nordisk; Bristol-Myers Squibb Company; AstraZeneca Pharmaceuticals LP; Boehringer Ingelheim Pharmaceuticals, Inc.; Takeda Pharmaceuticals North America, Inc.; Orexigen Therapeutics, Inc.

Stephen J. Nicholls, MBBS, PhD, FRACP

Stephen J. Nicholls, MBBS, PhD, FRACP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Boehringer Ingelheim Pharmaceuticals, Inc.; CSL Behring; Esperion Therapeutics, Inc.; Merck & Co., Inc.; Omthera Pharmaceuticals, Inc.; Roche; Takeda Pharmaceuticals North America, Inc.
Received grants for clinical research from: Anthera Pharmaceuticals; AstraZeneca Pharmaceuticals LP; Eli Lilly and Company; LipoScience Inc.; Novartis Pharmaceuticals Corporation; Resverlogix Corp; Roche

	Which of the following statements best describes your opinion regarding the 2013 ACC/AHA lipid guidelines in managing high-risk patients?
		I agree with high-efficacy statins and no recommended therapeutic goal
		I prefer the Canadian guidelines: ≥50% LDL-C lowering with statin therapy
		I prefer to continue to follow the ATP III guidelines
		I prefer the AACE guidelines: aggressive LDL-C and non-HDL-C targets
		I am confused about the new guidelines